UNSPSC 51171642: Prucalopride

This classification denotes a serotonin agonist with the molecular formula C18H26ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0A09IUW5TP, chemically known as 4-amino-5-chloro-2,3-dihydro-n-(1-(3-methoxypropyl)-4-piperidyl)-7-benzofurancarboxamide but generally known as prucalopride, which bears US NIH Compound Identifier 3052762. European Medicines Agency schedules Prucalopride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10155MIG.

UNSPSC 51171642 Prucalopride is a Commodity code for a specific pharmaceutical active ingredient, but recent state and local solicitations tagged with this code do not show actual procurement of prucalopride itself. Instead, issuing bodies are buying specimen collection and drug testing services, direct-to-manufacturer prescription program capabilities, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing agreements. The mismatch between the code's nominal scope and the actual work being solicited suggests this code sees limited relevant recent activity for prucalopride as a procurement line item.

Recent opportunities originate from diverse issuing bodies: Collin County Community Supervision and Corrections Department (RFP for offender specimen collection and drug testing services, due July 23, 2026), the Texas Health and Human Services Commission (RFI for direct-to-manufacturer prescription program vendor capabilities, response deadline April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance administered by the Minnesota Department of Administration (RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026). Geographic activity centers in Texas and the Upper Midwest, with the Minnesota cooperative serving multiple states including Oregon. The Collin County RFP, valued at approximately $600,000 over two years with optional renewals through five years total, represents the most concrete opportunity aligned to pharmaceutical procurement, though it focuses on testing services rather than prucalopride supply.